The uncertainty of the surgical margin in the treatment of head and neck cancer

被引:75
|
作者
Upile, T.
Fisher, C.
Jerjes, W.
El Maaytah, M.
Searle, A.
Archer, D.
Michaels, L.
Rhys-Evans, P.
Hopper, C.
Howard, D.
Wright, A.
机构
[1] Royal Natl Throat Nose & Ear Hosp, Dept Head & Neck Surg, Professorial Unit, London WC1X 8EE, England
[2] Royal Marsden Hosp, Dept Head & Neck Surg, London SW3 6JJ, England
[3] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England
[4] Eastman Dent Inst, Dept Oral & Maxillofacial Surg, London, England
[5] UCL Hosp, London, England
[6] Royal Marsden Hosp, Dept Plast & Reconstruct Surg, London SW3 6JJ, England
[7] Royal Marsden Hosp, Dept Head & Neck Surg, London SW3 6JJ, England
关键词
surgical margin; head and neck cancer; decision making; oncology; philosophy; surgery; head and neck surgery; maxillofacial surgery; plastic surgery;
D O I
10.1016/j.oraloncology.2006.08.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We discuss our surgical philosophy concerning the subtle interplay between the size of the surgical margin taken and the resultant morbidity from ablative oncological. procedures, which is ever more evident in the treatment of head and neck malignancy. The extent of tissue resection is determined by the "trade off" between cancer control and the perioperative, functional and aesthetic morbidity and mortality of the surgery. We also discuss our dilemmas concerning recent minimally invasive endoscopic microsurgical. techniques for the trans-oral laser removal. or co-ablation of aero-digestive tract tumours, which result in a minimal. surgical margin of oncological clearance. By a process of inductive argument as to the nature of the surgical margin, we consider whether the risks of taking a lesser margin with adjuvant therapy is justified by the attendant gain in reduced surgical morbidity and the possible costs in tumour control. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:321 / 326
页数:6
相关论文
共 50 条
  • [41] Surgical Salvage of Recurrent Cancer of the Head and Neck
    Zafereo, Mark
    CURRENT ONCOLOGY REPORTS, 2014, 16 (05)
  • [42] Surgical Treatment for Pulmonary Metastasis of Head and Neck Cancer: Study of 58 Cases
    Nakajima, Yuki
    Iijima, Yoshihito
    Kinoshita, Hiroyasu
    Akiyama, Hirohiko
    Beppu, Takeshi
    Uramoto, Hidetaka
    Hirata, Tomomi
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 23 (04) : 169 - 174
  • [43] HEAD AND NECK-CANCER REHABILITATION - TREATMENT OF POST-SURGICAL DYSPHAGIA
    FORSYTH, DM
    GLASSER, DB
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 1980, 61 (10): : 481 - 481
  • [45] Surgical Margin Definition and Assessment in Head and Neck Oncology: A Cross-Sectional Survey of Canadian Head and Neck Surgeons
    Daniel, Ryan C.
    Yan, Bernie
    Chandarana, Shamir
    Nichols, Anthony C.
    Eskander, Antoine
    Enepekides, Danny
    Higgins, Kevin
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2024, 53
  • [46] Head and neck cancer: treatment of nasopharyngeal cancer
    Chan, ATC
    ANNALS OF ONCOLOGY, 2005, 16 : 265 - 268
  • [47] Radioimmunotherapy for the treatment of head and neck cancer
    Karam, Sara D.
    Raben, David
    LANCET ONCOLOGY, 2019, 20 (08): : E404 - E416
  • [48] TREATMENT OF CANCER OF HEAD + NECK CHEMOTHERAPY
    BEAHRS, OH
    CALDAROLA, VT
    HARRISON, EG
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1964, 189 (10): : 765 - &
  • [49] Taxanes in the treatment of head and neck cancer
    Schrijvers, D
    Vermorken, JB
    CURRENT OPINION IN ONCOLOGY, 2005, 17 (03) : 218 - 224
  • [50] Ifosfamide in the treatment of head and neck cancer
    Airoldi, M
    Cortesina, G
    Giordano, C
    Pedani, F
    Bumma, C
    ONCOLOGY, 2003, 65 : 37 - 43